These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 7107081

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].
    Schuster O, Haertel M, Hugemann B, Gikalov I, Schiemann O, Fenner H.
    Arzneimittelforschung; 1985; 35(4):760-5. PubMed ID: 4015743
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Comparative study of the bioavailability and the pharmacodynamic effect of five allopurinol preparations (author's transl)].
    Jaeger H, Russmann D, Rasper J, Blome J.
    Arzneimittelforschung; 1982; 32(4):438-43. PubMed ID: 6896646
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bioavailability of allopurinol oral and rectal dosage forms.
    Chang SL, Kramer WG, Feldman S, Ballentine R, Frankel LS.
    Am J Hosp Pharm; 1981 Mar; 38(3):365-8. PubMed ID: 7223751
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D, Sripradit S, Angthararak S.
    J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
    [Abstract] [Full Text] [Related]

  • 9. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
    Mertz DP, Borner K.
    Med Welt; 1983 Sep 09; 34(36):974-9. PubMed ID: 6633222
    [No Abstract] [Full Text] [Related]

  • 10. [Comparison of the bioequivalence of two allopurinol preparations].
    Bührens K, Berndt P, Hilgenstock CM, Baumann W, Janzen D.
    Arzneimittelforschung; 1991 Mar 09; 41(3):250-3. PubMed ID: 1867662
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cerebrospinal fluid versus serum concentrations of 5-FU, allopurinol, and oxypurinol during treatment of metastatic brain cancer with 5-FU infusion, allopurinol, and radiation.
    Hornbeck CL, Floyd RA, Byfield JE, Griffiths JC, Frankel S, Sharp TR.
    Cancer Treat Rep; 1982 Mar 09; 66(3):571-3. PubMed ID: 7060045
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Difference of the plasma concentration and urinary excretion of allopurinol, oxypurinol, and purine bases between dietary intake and fasting.
    Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Yamakita J, Higashino K.
    Int J Clin Pharmacol Ther; 1996 Apr 09; 34(4):157-62. PubMed ID: 8861734
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Allopurinol: a comparative study of the bioavailability and effect on plasma uric acid of two products in tablet form.
    Nissen P, Pedersen L.
    Biopharm Drug Dispos; 1985 Apr 09; 6(4):441-6. PubMed ID: 4084669
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.